When a cancer patient is given a terminal diagnosis what is he/she supposed to do? When a cancer patient is given a therapy plan that, AT BEST, is supposed to prolong his/her life for only a month or two, what is the patient to do?
Conventional oncology has little to offer a pancreatic cancer patient. While the study below talks about low-dose naltrexone (LDN) combined with alpha-lipoic acid (ALA) lengthening life and enhancing quality of life for pancreatic cancer patients it is considered anecdotal evidence, advanced pancreatic cancer patients may appreciate information about non-toxic therapies.
Complimentary and integrative therapies listed in the articles linked and excerpted below have been shown to lengthen pancreatic overall survival while reducing side effects.
I take Life Extension Super bio Curcumin, vitamin C, alpha-lipoic acid and other supplements to remain in complete remission from my “incurable” cancer, multiple myeloma. Please read the articles below and consider supplementing with those nutriceuticals that you feel comfortable with.
For information about other complementary and integrative pancreatic cancer therapies such as Curcumin or omega 3 fatty acids, scroll down the page, post a question or a comment and I will reply ASAP.
Long-term cancer survivor, creator, director PeopleBeatingCancer
“The treatment regimen includes the intravenous alpha-lipoic acid and low-dose naltrexone (ALA-N) protocol and a healthy lifestyle program.
The patient was told by a reputable university oncology center in October 2002 that there was little hope for his survival. Today, January 2006, however, he is back at work, free from symptoms, and without appreciable progression of his malignancy.
The integrative protocol described in this article may have the possibility of extending the life of a patient who would be customarily considered to be terminal.
The authors believe that life scientists will one day develop a cure for metastatic pancreatic cancer, perhaps via gene therapy or another biological platform. But until such protocols come to market, the ALA-N protocol should be studied and considered, given its lack of toxicity at levels reported. Several other patients are on this treatment protocol and appear to be doing well at this time.
“Please consider moderate conventional therapies and combine them with evidence-based nutriceuticals linked below…”